Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.42 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.42 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6878025 | 0.87 | RXRA (0.62) | APPTTRRXRAPTPN1CA12 | |
| SCHEMBL6473808 | 0.85 | TTR (0.42) | APPTTRRXRAPTPN1EPHX2 | |
| SCHEMBL6473810 | 0.85 | TTR (0.42) | APPTTRRXRAPTPN1EPHX2 | |
| SCHEMBL6874284 | 0.79 | RXRA (0.50) | TTRRXRACA12CA1CA2 | |
| SCHEMBL6875694 | 0.79 | ALDH1A1 (0.46) | APPTTRRXRAPTPN1EPHX2 | |
| SCHEMBL6874716 | 0.78 | RXRA (0.52) | RXRACA12CA1CA2CA7 | |
| SCHEMBL6478564 | 0.77 | BCHE (0.43) | APPIP6K1IP6K3IP6K2CA12 | |
| SCHEMBL6478560 | 0.77 | BCHE (0.43) | APPIP6K1IP6K3IP6K2CA12 | |
| SCHEMBL7899451 | 0.77 | CYP26A1 (0.60) | APPTTRRXRAALDH1A1KDM4E | |
| SCHEMBL7899449 | 0.77 | CYP26A1 (0.60) | APPTTRRXRAALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825360-B1 | Bicyclic aromatic compounds | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-11-30 | — | — | US | disclosed |
| US-20030135053-A1 | For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics | BERNARDON JEAN-MICHEL | 2003-07-17 | — | — | US | disclosed |
| US-20030060491-A1 | Bicyclic aromatic compounds | BERNARDON JEAN-MICHEL (FR) | 2003-03-27 | — | — | US | disclosed |
| US-6515021-B1 | Bicyclic aromatic compounds | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2003-02-04 | — | — | US | disclosed |
| US-6147255-A | TOPICAL AND SYSTEMIC TREATMENT OF DERMATOLOGICAL COMPLAINTS ASSOCIATED WITH KERATINIZATION DISORDER WHICH HAS EFFECT ON DIFFERENTIATION AND ON PROLIFERATION | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060491-A1 | Bicyclic aromatic compounds | MITF, TYR, PAH | APP 3462/4885TTR 1024/4885RXRA 196/4885 |
| US-20030135053-A1 | For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics | MITF, TYR, PAH | APP 4362/4885TTR 771/4885RXRA 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.